Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Patients may experience increased salivation (sialorrhea) as a prodrome to nausea or vomiting, or conversely, may notice reduced appetite affecting their oral intake patterns
FDA is requesting that the risk be removed from the warnings and precautions section of labeling for the GLP-1 obesity drugs Eli Lilly and Co.s Zepbound (tirzepatide) and Novo Nordisk A/S Saxenda (liraglutide) and Wegovy (semaglutide)
Understanding Tirzepatide Dose Escalation Schedules Tirzepatide uses a deliberate titration schedule because starting at high doses causes severe nausea, vomiting, and diarrhea in most patients
Key symptoms Persistent feeling of dryness or stickiness in the mouth Thick, stringy saliva Difficulty speaking, chewing, or swallowing Altered taste sensation Cracked lips or sores at the corners of the mouth Increased thirst Potential oral health issues including bad breath and increased risk of dental decay How common is dry mouth with GLP-1 treatments
US$ 22.70
US$ 25.09
US$ 25.76
